Home » Drug & Device Pipeline News
Drug & Device Pipeline News
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Trials Authorized | |||
Hummingbird Bioscience | HMBD-002 | Cancers with VISTA-mediated immune suppression | IND approved by the FDA |
Instil Bio | ITIL-168 | Advanced melanoma | IND approved by the FDA |
Viewpoint Molecular Targeting | VMT-α-NET | Imaging of neuroendocrine tumors | IND approved by the FDA |
Telix Pharmaceuticals | TLX250 (177Lu-DOTA-girentuximab) | Kidney cancer | IND approved by the FDA |
Sigilon Therapeutics | SIG-005 | Mucopolysaccharidosis Type I | Phase 1/2 trial authorized by the UK regulatory authority |
Excision BioTherapeutics | EBT-101 | CRISPR-based therapy for chronic HIV | IND approved by the FDA |
Neurogene | NGN-101 | Batten disease | IND approved by the FDA |
Magenta Therapeutics | MGTA-117 | relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes | IND approved by the FDA |
Neovasc | COSIRA-II | Refractory angina | Investigational Device Exemption approved by the FDA |
Trials Initiated | |||
Alzamend Neuro | AL001 | Dementia related to Alzheimer’s disease | Initiation of phase 1 trial |
Celldex | Subcutaneous formulation of CDX-0159 | Chronic urticarias | Initiation of phase 1 trial |
Legend Biotech | LB1901 | Relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma | Initiation of phase 1 trial |
Pacylex Pharmaceuticals | PCLX-001 | NonHodgkins lymphomas and solid tumors | Initiation of phase 1 trial |
GammaDelta Therapeutics | GDX012 | Acute myeloid leukemia | Initiation of phase 1 trial |
Icosavax | IVX-121 | Respiratory syncytial virus/human metapneumovirus vaccine | Initiation of phase 1/1b trial |
ALX Oncology | ALX148 (evorpacept) with rituximab and lenalidomide | Indolent and aggressive nonHodgkins lymphoma | Initiation of phase 1/2 trial |
NLS Pharmaceuticals | Quilience | Excessive daytime sleepiness and cataplexy | Initiation of phase 2 trial |
Perception Neuroscience | PCN-101 (R-ketamine) | Treatment-resistant depression | Initiation of phase 2a trial |
DiaMedica Therapeutics | DM199 | Acute ischemic stroke | Initiation of phase 2/3 trial |
VistaGen Therapeutics | PH94B | Adults with social anxiety disorder | Initiation of phase 3 trial |
Zynerba Pharmaceuticals | Zygel (cannabidiol formulated in a transdermal gel) | Children and adolescents with Fragile X syndrome | Initiation of phase 3 trial |
Axsome Therapeutics | AXS-12 | Narcolepsy | Initiation of phase 3 trial |
Biogen | nusinersen | Later-onset spinal muscular atrophy | Initiation of phase 3 trial |
Approvals | |||
Visby Medical | Reverse transcription-polymerase chain reaction COVID-19 test | Pooled testing of up to five patient samples | Emergency Use Authorization (EUA) granted by the FDA |
Cepheid | Xpert Xpress CoV-2/Flu/RSV+ diagnostic test | COVID-19, influenza and respiratory syncytial virus | EUA granted by the FDA |
Quanterix | Simoa SARS-CoV-2 N protein antigen test | COVID-19 | EUA granted by the FDA |
BeiGene | Brukinsa (zanubrutinib) | Relapsed or refractory marginal-zone lymphoma | Approved by the FDA |
Takeda Pharmaceutical | Exkivity (mobocertinib) | EGFR Exon20 insertion+ nonsmall-cell lung cancer | Approved by the FDA |
Upcoming Events
-
07May
-
14May